Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera Maintenance in Elderly Follicular Lymphoma
NCT01144364Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2004
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Progression-Free Survival at 34 months. Started Jan 2004; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01144364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144364.